Latest
FDA approves biosimilar of Amgen’s Enbrel
![](https://dev.pacbiztimes.com/wp-content/uploads/2015/07/20-amgen-300x224.jpg)
The U.S. Food and Drug Administration formally approved a competing biosimilar of Amgen’s top-selling drug Enbrel on Aug. 30. Made by Switzerland-based Novartis, Erelzi mimics the effects of Enbrel. Enbrel, which was first approved in 1998, is approved to treat rheumatoid arthritis and other conditions by decreasing the amount of a protein produced by the Read More →
Read More →